Morphologic review of 1000 soft tissue sarcomas from the Scandinavian Sarcoma Group (SSG) Register

Meis‐Kindblom, Jeanne M.; Bjerkehage, Bodil; Böhling, Tom; Domanski, Henryk A.; Halvorsen, Tore; Larsson, Olle; Lilleng, Peer Kåre; Myhre-Jensen, Olaf; Stenwig, Elisabeth; Virolainen, Martti; Willén, Helena; Åkerman, Måns; Kindblom, Lars Gunnar

doi:10.1080/17453674.1999.11744818

Cited by 46 publications

(35 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…33 A standardized protocol was used for the review process. The LMS diagnoses for all tumors that were included were confirmed based on morphology that showed smooth muscle differentiation and positive immunohistochemical staining (IHC) for a-smooth muscle actin and desmin in most patients.…”

Section: Criteria For Inclusionmentioning

confidence: 99%

Clinical course of nonvisceral soft tissue leiomyosarcoma in 225 patients from the Scandinavian Sarcoma Group

Svarvar¹,

Böhling²,

Berlin³

et al. 2007

Cancer

Self Cite

127

133

View full text Add to dashboard Cite

BACKGROUND.Leiomyosarcoma of nonvisceral soft tissues is an uncommon malignant tumor; thus, only small numbers of cases have been reported. This study was based on a large series of patients from the Scandinavian Sarcoma Group Register acquired during a 15‐year period (from 1986 to 2001). Follow‐up information was available for all patients.METHODS.The authors analyzed the clinical features of 225 patients with cutaneous, subcutaneous, or deep‐seated leiomyosarcoma of the extremities, trunk wall, and superficial parts of the head and neck region to determine the natural course of the disease. Only patients who received their treatment at a specialist sarcoma center were included. Re‐evaluation of histopathology was performed.RESULTS.The age of the patients (121 women and 104 men) ranged from 20 years to 98 years (median, 70 years), and the tumors ranged in size from 0.6 cm to 35 cm (median, 4.0 cm). Eighty‐two percent of the tumors were classified as high grade. The median follow‐up for survivors was 5.5 years. The local treatment was adequate in 154 of 206 patients (75%) who were without metastasis at presentation. At 10 years, 84% of the 206 patients with localized disease at presentation were free from local recurrence, 66% remained metastasis free, and 49% were alive. Multivariate analysis showed that higher malignancy grade (P = .006), larger tumor size (P = .003), and deeper tumor location (P = .002) were correlated significantly with decreased metastasis‐free survival, inadequate local treatment was correlated with local recurrence (P = .007), and high malignancy grade was correlated with decreased overall survival (P = .007).CONCLUSIONS.The long‐term prognosis for patients with subcutaneous and deep‐seated soft tissue leiomyosarcoma remains poor despite the ability to achieve adequate local control through nonmutilating surgery with or without radiotherapy. Cancer 2007. © 2006 American Cancer Society.

show abstract

Section: Criteria For Inclusionmentioning

confidence: 99%

Clinical course of nonvisceral soft tissue leiomyosarcoma in 225 patients from the Scandinavian Sarcoma Group

Svarvar¹,

Böhling²,

Berlin³

et al. 2007

Cancer

Self Cite

127

133

View full text Add to dashboard Cite

show abstract

“…19,20 With regard to bone sarcomas, all osteosarcomas were high-grade malignant. Chondrosarcomas were graded in three grades and dedifferentiated.…”

Section: Microscopic Evaluation and Reporting Of Cnb And Surgical Excmentioning

confidence: 99%

Core-needle biopsy performed by the cytopathologist

Domanski

Åkerman

Carlén

et al. 2005

Cancer

Self Cite

View full text Add to dashboard Cite

“…During the last decade the histogenesis or line of differentiation of MFH has been debated among sarcoma pathologists. Based on thorough re-examination, including the clinical presentation and extensive immunostaining, sometimes also with the use of electron microscopy and genetic analyses, a line of differentiation can be demonstrated in many of the tumors previously classified as MFH [33,46,47,69,109]. Currently, MFH is diagnosed by ruling out other pleomorphic and myxoid sarcomas of specific lineage, foremost liposarcoma and leimyosarcoma, as well as carcinomas, melanomas and lymphomas [48,90,93,112].…”

Section: Histopathologymentioning

confidence: 99%

“…The two malignancy grading systems most commonly used are the National Cancer Institute (NCI) system used in North America, and the Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) system used in most parts of Europe [23,31]. In Scandinavia, Sweden, Norway and Finland use a IV-tiered histological malignancy grading system based on cellularity, pleomorphism, nuclear atypia, tumor necrosis and mitotic rate [6,107,109], whereas a III-tiered system is used in Denmark [120]. High malignancy grade is a strong prognostic factor for metastasis [25,55,116,165,193].…”

Section: Malignancy Gradementioning

confidence: 99%

See 1 more Smart Citation

Prognostic factors in soft tissue sarcomaTissue microarray for immunostaining, the importance of whole-tumor sections and time-dependence

Engellau¹

2004

Acta Orthopaedica Scandinavica

View full text Add to dashboard Cite

Morphologic review of 1000 soft tissue sarcomas from the Scandinavian Sarcoma Group (SSG) Register

Cited by 46 publications

References 21 publications

Clinical course of nonvisceral soft tissue leiomyosarcoma in 225 patients from the Scandinavian Sarcoma Group

Clinical course of nonvisceral soft tissue leiomyosarcoma in 225 patients from the Scandinavian Sarcoma Group

Core-needle biopsy performed by the cytopathologist

Prognostic factors in soft tissue sarcomaTissue microarray for immunostaining, the importance of whole-tumor sections and time-dependence

Contact Info

Product

Resources

About